Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study

Sabine Visser1,2,3, Jeannine Huisbrink4,5, Nils E. van ’t Veer4, Jermo J. van Toor2, Anton J.M. van Boxem6, Nico C. van Walree1, Bruno H. Stricker3,7 and Joachim G.J.V. Aerts1,2

Affiliations: 1Dept of Pulmonary Medicine, Amphia Hospital, Breda, The Netherlands. 2Dept of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 3Dept of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. 4Dept of Clinical Pharmacy, Amphia Hospital, Breda, The Netherlands. 5Dept of Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. 6Dept of Pulmonary Medicine, Bravis Hospital, Roosendaal, The Netherlands. 7Inspectorate of Health Care, Utrecht, The Netherlands.

Correspondence: Bruno H. Stricker, Dept of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: b.stricker@erasmusmc.nl

There is a significant risk of renal impairment during pemetrexed maintenance, which may jeopardise further treatment.


ABSTRACT  Optimal survival benefit from different lines of anticancer treatment in advanced nonsmall cell lung cancer (NSCLC) requires conservation of renal function. We evaluated the development of renal impairment during pemetrexed maintenance.

In a prospective multicentre cohort study, we evaluated the incidence of acute/chronic kidney disease (AKD/CKD), its related treatment discontinuation frequency and associated clinical variables with AKD in patients with stage IIIIB/IV NSCLC treated with pemetrexed maintenance. We validated the findings in an independent cohort.

190 patients received pemetrexed. In the primary cohort, 149 patients started induction, of whom 44 patients (30%) continued maintenance. In the independent cohort, 41 patients received maintenance. During maintenance 13 patients (30%) developed AKD, leading to CKD and treatment discontinuation in eight patients (62%) in the primary cohort. Higher estimated glomerular filtration rate (eGFR) (per unit 5 mL·min⁻¹ per 1.73 m²) before maintenance and induction (OR 0.70, 95% CI 0.54–0.90 and OR 0.78, 95% CI 0.62–0.98, respectively) and relative decline (per 10%) in eGFR during induction (OR 2.54, 95% CI 1.36–4.74) were associated with AKD during maintenance. In the independent cohort, 20 patients (49%) developed AKD, leading to CKD in 11 patients (55%) and treatment discontinuation in six patients (30%).

Patients are at risk for renal impairment during pemetrexed maintenance, which may jeopardise further lines of anticancer treatment.
**Introduction**

Pemetrexed is widely used as first- and second-line treatment in nonsquamous nonsmall cell lung cancer (NSCLC) without actionable driver mutations or high programmed death ligand 1 (PD-L1) expression [1]. More recently, first-line platinum-based treatment with pemetrexed combined with pembrolizumab prolonged overall survival compared with chemotherapy regardless of PD-L1 expression [2]. In patients without disease progression after platinum-based induction therapy, pemetrexed is recommended as maintenance treatment [3–6]. Both immunotherapy and the combination of docetaxel with antiangiogenic agents have demonstrated their superior efficacy compared with conventional chemotherapy, and have been approved for second-line treatment [7, 8]. However, to gain optimal survival benefit from all these agents, patients should be able to start as well as continue multiple lines of treatment for which it is required to maintain an adequate renal function [9, 10].

Patients with (lung) cancer are at increased risk of developing acute kidney injury (AKI) [11]. In addition to exposure to nephrotoxic chemotherapeutic agents, decline in renal function in these patients is due to cancer- or chemotherapy-induced true or effective volume depletion, the advanced age of the patients and nephrotoxic concomitant medication [12]. The mechanism of renal injury by pemetrexed is postulated to be mainly tubulointerstitial, as pemetrexed enters the proximal tubular cells at the basolateral membrane by the reduced folate carrier and is transported through the folate receptor at its apical site. Once inside the tubular cells, pemetrexed undergoes polyglutamylation that results in intracellular retention and an increase in affinity towards enzymes involved in folate metabolism, leading to tubular injury due to impaired DNA synthesis [12, 13]. Although pemetrexed administration is not recommended in patients with a creatinine clearance <45 mL·min⁻¹ per 1.73 m² [14], studies have shown that even milder pre-existing renal impairment is a risk factor for drug-induced nephrotoxicity [15, 16].

Irrespective of its nature, AKI is a predictor of immediate and long-term unfavourable outcomes [17–19]. Moreover, AKI is an important risk factor for the development of chronic kidney disease (CKD) [20] and may jeopardise further cancer treatment [21]. Sustained impairment of the kidney function after discontinuation of pemetrexed maintenance therapy has been described in several case reports [22, 23]. The PARAMOUNT study (a study of induction and maintenance treatment of advanced nonsquamous NSCLC) reported renal impairment in <10% of the patients treated with pemetrexed maintenance and <5% of the patients discontinued treatment due to renal toxicity [24]. However, this trial population was highly selected and might underestimate the risk and consequences of renal toxicity in daily clinical practice.

Therefore, our objective was to describe the development of acute and chronic renal impairment during maintenance treatment with pemetrexed, and its impact on treatment decisions in a real-world setting.

**Materials and methods**

**Prospective multicentre cohort (primary cohort)**

The PERSONAL (PEmetrexed and biomarkerS: an observatiONAL) study is a prospective multicentre cohort study of adult patients with locally advanced or metastatic (stage IIIB/IV) nonsquamous NSCLC and unresectable mesothelioma receiving platinum-combined pemetrexed as first-line treatment and pemetrexed monotherapy as second-line treatment. Patients were recruited between October 2012 and November 2014 from a university hospital (Erasmus University Medical Center, Rotterdam), two large teaching hospitals specialised in lung cancer care (Amphia Hospital, Breda and Franciscus Gasthuis & Vlietland, Rotterdam) and a regional hospital (Bravis Hospital, Roosendaal) in the Netherlands. Patients who received pemetrexed as second-line treatment and patients with unresectable mesothelioma were excluded from analyses in the present study. The PERSONAL cohort will be denoted as the “primary cohort” in this article. All patients provided written informed consent. The study was approved by the Institutional Review Board of the Erasmus University Medical Center.

Per standard of care, platinum-combined pemetrexed chemotherapy was administered as an intravenous infusion every 3 weeks for a maximum of 4 cycles. The administered dosages of pemetrexed and cisplatin were calculated according to the body surface area (500 and 75 mg·m⁻², respectively) [14]. Carboplatin dosage was calculated based on estimated glomerular filtration rate (eGFR) and the target area under the curve values of 5 or 6 following the Calvert formula [25]. If the chemotherapy schedule involved cisplatin, pre- and post-hydration treatment was given per protocol. Patients were recommended to continue with pemetrexed maintenance therapy if they had no progressive disease, no intolerable toxicities and underwent no sequential radiotherapy or surgery.

Baseline serum creatinine (µmol·L⁻¹) was obtained prior to the initial chemotherapy cycle. Subsequently, serum creatinine was measured prior to and weekly after each chemotherapy administration during the induction therapy. During maintenance treatment blood samples were only extracted prior to pemetrexed
administration and at day 14 of each cycle. Estimations of renal function were made by calculation of the eGFR (mL·min$^{-1}$ per 1.73 m$^2$) using the Chronic Kidney Disease Epidemiology Collaboration equation [26]. Renal adverse events were registered according to the Common Terminology Criteria of Adverse Events (CTCAE) version 3.0, for comparison with the registration trial of pemetrexed maintenance [24], and the updated version 4.03 (table 1).

Independent cohort
To validate findings in the primary cohort, we selected all patients with advanced NSCLC who started treatment with pemetrexed maintenance between November 2014 and December 2016 in one hospital (Amphia Hospital). We used the pharmacy database of this centre to construct a second independent cohort of patients who received pemetrexed maintenance treatment after patient enrolment in the PERSONAL study had finished. Prior to maintenance treatment, these patients received first-line platinum-combined induction treatment with pemetrexed and hydration per standard of care (see previous section) creatinine level before start of induction and maintenance, and during maintenance prior to each pemetrexed administration. As data in this cohort were collected retrospectively, no approval by a medical research and ethics committee was necessary according to Dutch guidelines.

Definitions of acute and chronic kidney disease
In both cohorts, patients with acute kidney disease (AKD) and CKD during induction and maintenance therapy were identified in accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines (table 2) [27, 28].

In addition to the development of CKD, we registered clinical consequences related to decreased renal function in terms of discontinuation of therapy, hospitalisation, and dose adjustments and postponements.

Statistical analysis
Sociodemographic and clinical variables were described for all patients who were included in both cohorts. Patients from the primary cohort who underwent maintenance treatment were categorised into two groups (eGFR <90 versus ≥90 mL·min$^{-1}$ per 1.73 m$^2$) according to their renal function at baseline (start of induction treatment) and at the start of maintenance therapy. For these groups, we reported the percentages of patients with AKD, CKD and clinical consequences with 95% confidence intervals calculated using the Wilson score method. The difference in incidence of AKD between these groups was examined using the Chi-squared or Fisher’s exact test. With the use of logistic regression, we determined the univariate association of renal function before induction and maintenance (per unit eGFR of

<table>
<thead>
<tr>
<th>TABLE 1 Renal adverse events according to the Common Terminology Criteria of Adverse Events (CTCAE)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Version</strong></td>
</tr>
<tr>
<td>CTCAE 3.0</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>CTCAE 4.03</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

eGFR: estimated glomerular filtration rate.

<table>
<thead>
<tr>
<th>TABLE 2 Kidney Disease: Improving Global Outcomes clinical practice guidelines for identification of acute kidney disease (AKD) and chronic kidney disease (CKD)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AKD</strong></td>
</tr>
<tr>
<td><strong>CKD</strong></td>
</tr>
</tbody>
</table>

$^a$: in patients with a baseline eGFR <60 mL·min$^{-1}$ per 1.73 m$^2$ only changes in eGFR and serum creatinine during the next 3 months were used as criteria for AKD.
5 mL·min$^{-1}$ per 1.73 m$^2$), change of renal function during induction (relative to baseline per 10%), and other patient- and treatment-related factors with the incidence of AKD during maintenance. To verify findings from our prospective cohort study, we repeated these analyses in the second independent cohort. All statistical analyses were performed using SPSS version 22.0 (IBM, Armonk, NY, USA). $p<0.05$ was considered as statistically significant.

Results
In total, 190 patients who received treatment with pemetrexed were included in the current study. In the primary cohort, 149 patients with advanced NSCLC who started first-line induction treatment with pemetrexed were enrolled. Of these, 44 patients (29.5%) ultimately received one or more cycles of pemetrexed maintenance treatment (figure 1). The second independent cohort consisted of 41 patients with advanced NSCLC who had received one or more cycles cycle of pemetrexed maintenance therapy after first-line induction treatment.

All patient and treatment characteristics of patients in both cohorts are outlined in table 3. In the primary cohort, a higher percentage of patients with maintenance pemetrexed ($n=44$) had metastatic disease ($p=0.003$) and they had higher serum albumin ($p=0.001$) than patients who only received induction treatment ($n=105$). Between patients who underwent maintenance in both cohorts, there were no significant differences and platinum combination treatments were similar. Slightly more female patients underwent pemetrexed maintenance in the second independent cohort than in the primary cohort (65.9% versus 50.0%; $p=0.188$). Median (interquartile range (IQR)) follow-up time was 3.2 (1.9–6.1) months in the second independent cohort and 3.5 (1.4–8.3) months in the primary cohort.

![Flowchart of patients in the primary cohort. RT: radiotherapy; MPM: malignant pleural mesothelioma; CISPEM: combined cisplatin and pemetrexed; CARPEM: combined carboplatin and pemetrexed; PD: progressive disease.](https://doi.org/10.1183/13993003.00884-2018)
Renal impairment in the primary cohort

Induction treatment

Calculated eGFR values at baseline were significantly different between the patients treated with combined cisplatin and pemetrexed (CISPEM) and with combined carboplatin and pemetrexed (CARPEM) (98.1 ±16.0 versus 88.7±15.9 mL·min⁻¹ per 1.73 m²; p=0.001). Over the total induction treatment of 4 cycles, the mean eGFR decreased in patients treated with CISPEM (n=53) in contrast to the mean eGFR in patients treated with CARPEM (n=29) (−9.1±9.5 versus −2.0±11.0 mL·min⁻¹ per 1.73 m²; p=0.003). Weekly median eGFR values of patients receiving combined platinum induction treatment are described in the supplementary material.

Maintenance

The median (IQR) number of maintenance pemetrexed cycles was 5 (2–12) and the eGFR before administration of the first maintenance cycle was 86.3 (71.6–97.2) mL·min⁻¹ per 1.73 m². During maintenance treatment with pemetrexed 13 out of the 44 patients (29.5%) developed AKD according to KDIGO definitions. From these 13 patients, 10 patients (77%) had all-grades renal adverse events according to CTCAE 4.03 compared with only seven patients (54%) using CTCAE 3.0. Hence, using CTCAE 3.0 we found only 16% of patients experienced renal adverse events.

Individual courses of patients’ renal function are shown in figure 2. Compared with patients with eGFR ≥90 mL·min⁻¹ per 1.73 m² at the start of maintenance, patients with a mildly decreased renal function (eGFR <90 mL·min⁻¹ per 1.73 m²) more frequently developed AKD (11 out of 23 versus two out of 21;
and their renal function more often decreased below the recommendation threshold of pemetrexed administration (eGFR <45 mL·min$^{-1}$ per 1.73 m$^2$) when compared with the control group (one out of 21; $p=0.017$). Two patients with eGFR <45 mL·min$^{-1}$ per 1.73 m$^2$ already before maintenance were excluded from this analysis.

Per unit $5\,\text{mL}·\text{min}^{-1}$ per 1.73 m$^2$, higher eGFR values both before maintenance and before induction treatment were associated with a lower risk of AKD (OR 0.70, 95% CI 0.54–0.90 and OR 0.78, 95% CI 0.62–0.98, respectively) (table 4). In contrast, a 10% decline in eGFR during induction relative to baseline was associated with an increased probability of AKD (OR 2.54, 95% CI 1.36–4.74). In patients with AKD the mean±SD decrease of eGFR during induction was $-12.2±8.9\,\text{mL}·\text{min}^{-1}$ per 1.73 m$^2$ compared with $-2.1±8.4\,\text{mL}·\text{min}^{-1}$ per 1.73 m$^2$ in patients without AKD.

**Clinical implications**

The development of CKD and clinical consequences of renal impairment during maintenance therapy are outlined in figure 3. Of the 13 patients (30%) who developed AKD during maintenance therapy, eight patients (62%) ultimately developed CKD. Eight of the 13 patients with AKD (62%) were forced to

---

**FIGURE 2** Renal function and development of acute kidney disease (AKD) during pemetrexed maintenance therapy in the primary cohort ($n=44$). eGFR: estimated glomerular filtration rate. a) eGFR $\geq 90\,\text{mL}·\text{min}^{-1}$ per 1.73 m$^2$ ($n=21$) and b) eGFR <90 mL·min$^{-1}$ per 1.73 m$^2$ ($n=23$). Data are presented as individual measurements of renal function together with course of renal function during maintenance therapy of individuals who developed AKD and did not develop AKD. The dashed red line indicates eGFR=45 mL·min$^{-1}$ per 1.73 m$^2$, the value below which pemetrexed administration is not recommended.

---

https://doi.org/10.1183/13993003.00884-2018
discontinue maintenance treatment due to renal impairment. Importantly, all of these patients who developed CKD and stopped treatment already had mildly impaired renal function (\(<90 \text{ mL·min}^{-1} \text{ per } 1.73 \text{ m}^2\)) before the start of maintenance. Moreover, in patients whose renal function was already mildly impaired before induction (\(<90 \text{ mL·min}^{-1} \text{ per } 1.73 \text{ m}^2\)) the proportion of patients who had to discontinue treatment was higher than in patients with a normal eGFR (six out of 11 versus two out of 33; \(p=0.001\)). Accordingly, patients more often developed AKD (six out of 11 versus seven out of 33; \(p=0.057\)) and CKD (five out of 11 versus three out of 33; \(p=0.016\)) if renal function was mildly impaired before induction.

Renal impairment in the second independent cohort

In the second independent cohort, the median (IQR) number of maintenance pemetrexed cycles was 4 (3–8) and the eGFR before administration of the first maintenance cycle was 80.6 (63.4–93.3) mL·min\(^{-1}\) per 1.73 m\(^2\). 20 patients (49%) developed AKD, of whom 11 patients (55%) eventually developed CKD and six patients (30%) discontinued pemetrexed maintenance. Similar to the primary cohort, all patients who developed CKD and stopped maintenance treatment had eGFR <90 mL·min\(^{-1}\) per 1.73 m\(^2\) at start of maintenance.

We tested the same patient- and treatment-related variables for their relation with the development of AKD during maintenance as in the primary cohort (table 4). Again, per unit 5 mL·min\(^{-1}\) per 1.73 m\(^2\), higher eGFR values before maintenance and before induction treatment were univariably associated with a

### TABLE 4 Univariate analysis of clinical and treatment-related factors associated with acute kidney disease during pemetrexed maintenance

<table>
<thead>
<tr>
<th>Primary cohort(^a)</th>
<th>Independent cohort(^\ddagger)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OR (95% CI)</strong></td>
<td><strong>p-value</strong></td>
</tr>
<tr>
<td>Age</td>
<td>1.07 (0.98–1.18)</td>
</tr>
<tr>
<td>Sex: male versus female</td>
<td>0.52 (0.14–1.93)</td>
</tr>
<tr>
<td>History of cardiovascular disease: yes versus no</td>
<td>0.70 (0.18–2.80)</td>
</tr>
<tr>
<td>CISPEM during induction: yes versus no</td>
<td>2.62 (0.49–14.11)</td>
</tr>
<tr>
<td>Number of cycles pemetrexed maintenance</td>
<td>1.08 (1.0–1.17)</td>
</tr>
<tr>
<td>eGFR decrease during induction(^*)</td>
<td>2.54 (1.36–4.74)</td>
</tr>
<tr>
<td>eGFR before induction(^\ddagger)</td>
<td>0.78 (0.62–0.98)</td>
</tr>
<tr>
<td>eGFR before maintenance(^\ddagger)</td>
<td>0.70 (0.54–0.90)</td>
</tr>
</tbody>
</table>

CISPEM: combined cisplatin and pemetrexed; eGFR: estimated glomerular filtration rate. \(^a\): \(n=44\); \(^\ddagger\): \(n=41\); \(^*\): eGFR change relative to baseline per 10%; \(^\ddagger\): eGFR per unit 5 mL·min\(^{-1}\) per 1.73 m\(^2\).
lower probability of AKD during maintenance (OR 0.64, 95% CI 0.48–0.84 and OR 0.78, 95% CI 0.62–0.98, respectively). Also, a 10% decline in eGFR during induction compared with baseline was related to an increased risk of AKD (OR 1.56, 95% CI 1.03–2.36).

Discussion
In an era of accelerated development and adaptation of new agents with survival benefits for patients with advanced NSCLC, it becomes increasingly important to ascertain patients who are able to start and continue multiple lines of treatment. Our study shows serious concerns with regard to the preservation of an adequate renal function during pemetrexed maintenance therapy, which might expose patients to a suboptimal oncological treatment. In a real-world setting, one-third of patients with metastatic NSCLC developed AKD during pemetrexed maintenance therapy and half of these patients were forced to discontinue maintenance treatment. Moreover, in the majority of patients with AKD renal function did not recover (or only partially recovered) and these patients developed CKD. Importantly, these results were verified in an independent cohort of patients with advanced NSCLC treated with pemetrexed maintenance.

Approximately 20% lower risk of occurrence of AKD during pemetrexed maintenance therapy was observed in patients per 5 mL·min\(^{-1}\) per 1.73 m\(^2\) higher eGFR before the start of induction therapy. The proportions of patients who developed AKD, CKD and who discontinued maintenance treatment were significantly higher in patients with impaired renal function (eGFR <90 mL·min\(^{-1}\) per 1.73 m\(^2\)) at the start of maintenance and before induction. It has already been recognised that decreased renal function, even mildly, can predispose to chemotherapy-induced nephrotoxicity [15, 29]. SASSER et al. [30] also reported a linkage between renal impairment before maintenance treatment and the higher probability of discontinuing double maintenance therapy with pemetrexed and bevacizumab. In contrast to our study, they did not find an association between renal function before induction and treatment discontinuation. In addition to almost 20% missing data of renal function before induction and a lack of patients with eGFR <60 mL·min\(^{-1}\) per 1.73 m\(^2\) at baseline in that study, the different pathophysiology leading to renal damage due to bevacizumab might explain this difference.

During pemetrexed maintenance, patients were at ∼2-fold higher risk of developing AKD per 10% decline of eGFR during induction therapy relative to baseline. Patients treated with CISPEM showed a decline in eGFR of ∼10 mL·min\(^{-1}\) per 1.73 m\(^2\), which is comparable to recent findings in patients who received cisplatin for treatment across multiple tumour types [13]. As treatment with CISPEM during induction therapy was not associated with AKD throughout the maintenance period, it is unlikely that nephrotoxicity during maintenance is solely a delayed cisplatin effect. This is supported by findings of follow-up studies in patients with various cancer types, including lung cancer, which demonstrated that declines in eGFR did not deteriorate after discontinuation of cisplatin [13, 31]. Although not statistically significant (p=0.06), AKD occurred more often in patients who received a higher number of pemetrexed maintenance cycles. A cumulative systemic dose of pemetrexed might play a role in the development of nephrotoxicity in these patients, as also recently suggested by LANGER et al. [32].

The nephrotoxic potential of pemetrexed has been described previously in clinical studies. In the pivotal PARAMOUNT trial [3], PUJOL et al. [24] reported all-grades renal toxicities according to CTCAE 3.0 in 7.8% of patients and treatment discontinuation in 4.5% of patients due to renal impairment during pemetrexed maintenance. Acknowledging small patient numbers, our study notes probable underestimation of renal toxicity by using CTCAE 3.0 compared with AKD (KDIGO). By taking into account absolute increases of creatinine and its relative increase from baseline, the results of the updated CTCAE 4.03 corresponded better with the AKD results. Additionally, the patient population in the PARAMOUNT trial was highly selected with regard to Eastern Cooperative Oncology Group performance status, renal function at baseline and concomitant medication, as opposed to our real-life population. Therefore, that trial probably underestimates the risk of renal insufficiency in daily practice. Although pemetrexed maintenance was combined with bevacizumab and therefore results cannot solely be attributed to pemetrexed, SASSER et al. [30] reported renal adverse events resulting in treatment discontinuation in 17% of patients.

Due to a low event-rate number per subgroup in the primary and independent cohort, we could not perform a multivariate analysis to identify patient- and treatment-related variables associated with the development of AKD during maintenance therapy. As both cohorts differed with regard to frequency and timing of data collection of renal function by design, we did not consider it suitable to perform a combined analysis of these cohorts. We cannot exclude effect modification by the platinum compound, as all patients received CISPEM or CARPEM during induction treatment without a pemetrexed monotherapy comparator arm.

In conclusion, the results of this study in a real-life setting demonstrate that patients with advanced NSCLC are at risk to develop renal impairment during pemetrexed maintenance therapy. This has important clinical consequences, as the majority of these patients develop CKD, ∼15–20% are forced to
stop maintenance treatment and further anticancer treatment may be jeopardised. Increased awareness and further exploration of renal protective strategies for patients at increased risk might be beneficial, such as continuation of hydration during pemetrexed maintenance.

Acknowledgements: We thank Hans in ‘t Veen (Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands) for providing data.

Conflict of interest: S. Visser reports grants from ZonMw (grant number 152001017), during the conduct of the study. J. Huisbrink has nothing to disclose. N.E. van ’t Vee has nothing to disclose. J.J. van Toor has nothing to disclose. A.J. M. van Boxem has nothing to disclose. N.C. van Walsee has nothing to disclose. B.H. Stricker reports grants from ZonMw (grant number 152001017), during the conduct of the study. J.G.J.V. Aerts reports grants from ZonMw (grant number 152001017), during the conduct of the study; and has consultant/advisory roles with Eli Lilly and Company, Roche, Bristol-Myers Squibb, MSD and Boehringer Ingelheim, outside the submitted work.

Support statement: This work was supported by the Netherlands Organisation for Health Research and Development (ZonMw) (grant number 152001017). Funding information for this article has been deposited with the Crossref Funder Registry.

References


